Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Return on Equity (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Return on Equity data on record, last reported at 0.32% in Q3 2023.

  • For Q3 2023, Return on Equity fell 46.0% year-over-year to 0.32%; the TTM value through Sep 2023 reached 0.32%, down 46.0%, while the annual FY2022 figure was 0.23%, 44.0% up from the prior year.
  • Return on Equity reached 0.32% in Q3 2023 per CGEM's latest filing, down from 0.29% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.17% in Q2 2022 and bottomed at 0.41% in Q4 2020.
  • Average Return on Equity over 4 years is 0.1%, with a median of 0.15% recorded in 2021.
  • The widest YoY moves for Return on Equity: up 36bps in 2023, down -47bps in 2023.
  • A 4-year view of Return on Equity shows it stood at 0.41% in 2020, then soared by 62bps to 0.15% in 2021, then soared by 200bps to 0.16% in 2022, then plummeted by -308bps to 0.32% in 2023.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.32% in Q3 2023, 0.29% in Q2 2023, and 0.12% in Q1 2023.